CRINETICS Trademark
Trademark Overview
On Friday, March 17, 2023, a trademark application was filed for CRINETICS with the United States Patent and Trademark Office. The USPTO has given the CRINETICS trademark a serial number of 97844217. The federal status of this trademark filing is SU - REGISTRATION REVIEW COMPLETE as of Monday, December 9, 2024. This trademark is owned by Crinetics Pharmaceuticals, Inc.. The CRINETICS trademark is filed in the Pharmaceutical Products and Computer & Software Services & Scientific Services categories with the following description:
Pharmaceutical preparations for modulating neuropeptides and G-protein coupled receptors (GPCRs); pharmaceutical preparations for use in oncology; pharmaceutical preparations for use in treating endocrine disorders and endocrine related diseases; pharmaceutical preparations for targeting neuropeptide receptors; pharmaceutical preparations for the treatment of cancer, acromegaly, neuroendocrine tumors, Cushing's Disease, hyperinsulinism, carcinoid syndrome, congenital adrenal hyperplasia, hypercalcemia, chronic pain, hyperparathyroidism, polycystic kidney disease, Grave's disease, thyroid eye disease, thyroid ophthalmopathy, diabetes, obesity, insulinoma, hypoglycemia, androgen deficiency, infertility, thyroid cancer, growth hormone deficiency, hypoparathyroidism, nonfunctional pituitary adenomas, polycystic liver disease, and type two diabetes; therapeutic preparations for the treatment of ocular diseases and disorders, metabolic diseases and disorders, hormonal diseases and disorders,...
Medical research services; scientific research and development; pharmaceutical research and development; therapeutic research and development, namely, research and development of therapeutic preparations; research and development in the field of oncology; medical research for treating cancer, endocrine disorders, acromegaly, neuroendocrine tumors, Cushing's Disease, hyperinsulinism, chronic pain, hypercalcemia, hyperparathyroidism, polycystic kidney disease, Grave's disease, thyroid eye disease, thyroid ophthalmopathy, diabetes, obesity, insulinoma, hypoglycemia, androgen deficiency, infertility, thyroid cancer, growth hormone deficiency, hypoparathyroidism, nonfunctional pituitary adenomas, polycystic liver disease, and type two diabetes; pharmaceutical research for treating cancer, endocrine disorders, acromegaly, neuroendocrine tumors, Cushing's Disease, hyperinsulinism, and chronic pain, hypercalcemia, hyperparathyroidism, polycystic kidney disease, Grave's disease, thyroid eye dis...
General Information
| Serial Number | 97844217 |
| Word Mark | CRINETICS |
| Filing Date | Friday, March 17, 2023 |
| Status | 819 - SU - REGISTRATION REVIEW COMPLETE |
| Status Date | Monday, December 9, 2024 |
| Registration Number | 0000000 |
| Registration Date | NOT AVAILABLE |
| Mark Drawing | 4 - Illustration: Drawing with word(s) / letter(s) / number(s) in Block form |
| Published for Opposition Date | Tuesday, January 30, 2024 |
Trademark Statements
| Goods and Services | Pharmaceutical preparations for modulating neuropeptides and G-protein coupled receptors (GPCRs); pharmaceutical preparations for use in oncology; pharmaceutical preparations for use in treating endocrine disorders and endocrine related diseases; pharmaceutical preparations for targeting neuropeptide receptors; pharmaceutical preparations for the treatment of cancer, acromegaly, neuroendocrine tumors, Cushing's Disease, hyperinsulinism, carcinoid syndrome, congenital adrenal hyperplasia, hypercalcemia, chronic pain, hyperparathyroidism, polycystic kidney disease, Grave's disease, thyroid eye disease, thyroid ophthalmopathy, diabetes, obesity, insulinoma, hypoglycemia, androgen deficiency, infertility, thyroid cancer, growth hormone deficiency, hypoparathyroidism, nonfunctional pituitary adenomas, polycystic liver disease, and type two diabetes; therapeutic preparations for the treatment of ocular diseases and disorders, metabolic diseases and disorders, hormonal diseases and disorders, reproductive diseases and disorders, bone diseases and disorders, digestive diseases and disorders, gastroenterological diseases and disorders, and thyroid diseases and disorders |
| Goods and Services | Medical research services; scientific research and development; pharmaceutical research and development; therapeutic research and development, namely, research and development of therapeutic preparations; research and development in the field of oncology; medical research for treating cancer, endocrine disorders, acromegaly, neuroendocrine tumors, Cushing's Disease, hyperinsulinism, chronic pain, hypercalcemia, hyperparathyroidism, polycystic kidney disease, Grave's disease, thyroid eye disease, thyroid ophthalmopathy, diabetes, obesity, insulinoma, hypoglycemia, androgen deficiency, infertility, thyroid cancer, growth hormone deficiency, hypoparathyroidism, nonfunctional pituitary adenomas, polycystic liver disease, and type two diabetes; pharmaceutical research for treating cancer, endocrine disorders, acromegaly, neuroendocrine tumors, Cushing's Disease, hyperinsulinism, and chronic pain, hypercalcemia, hyperparathyroidism, polycystic kidney disease, Grave's disease, thyroid eye disease, thyroid ophthalmopathy, diabetes, obesity, insulinoma, hypoglycemia, androgen deficiency, infertility, thyroid cancer, growth hormone deficiency, hypoparathyroidism, nonfunctional pituitary adenomas, polycystic liver disease, and type two diabetes; therapeutic research, namely, research of therapeutic preparations for ocular diseases and disorders, metabolic diseases and disorders, hormonal diseases and disorders, reproductive diseases and disorders, bone diseases and disorders, digestive diseases and disorders, gastroenterological diseases and disorders, and thyroid diseases and disorders; providing medical and scientific research information in the fields of pharmaceuticals and therapeutics |
Classification Information
| International Class | 005 - Pharmaceutical and veterinary preparations; sanitary preparations for medical purposes; dietetic substances adapted for medical use, food for babies; plasters, materials for dressings; material for stopping teeth, dental wax; disinfectants; preparations for destroying vermin; fungicides, herbicides. |
| US Class Codes | 005, 006, 018, 044, 046, 051, 052 |
| Class Status Code | 6 - Active |
| Class Status Date | Sunday, April 9, 2023 |
| Primary Code | 005 |
| First Use Anywhere Date | Friday, December 7, 2018 |
| First Use In Commerce Date | Friday, December 7, 2018 |
| International Class | 042 - Scientific and technological services and research and design relating thereto; industrial analysis and research services; design and development of computer hardware and software. |
| US Class Codes | 100, 101 |
| Class Status Code | 6 - Active |
| Class Status Date | Sunday, April 9, 2023 |
| Primary Code | 042 |
| First Use Anywhere Date | Wednesday, May 12, 2021 |
| First Use In Commerce Date | Wednesday, May 12, 2021 |
Trademark Owner History
| Party Name | Crinetics Pharmaceuticals, Inc. |
| Party Type | 20 - Owner at Publication |
| Legal Entity Type | 03 - Corporation |
| Address | San Diego, CA 92121 |
| Party Name | Crinetics Pharmaceuticals, Inc. |
| Party Type | 10 - Original Applicant |
| Legal Entity Type | 03 - Corporation |
| Address | San Diego, CA 92121 |
Trademark Events
| Event Date | Event Description |
| Tuesday, March 21, 2023 | NEW APPLICATION ENTERED |
| Sunday, April 9, 2023 | NEW APPLICATION OFFICE SUPPLIED DATA ENTERED |
| Monday, October 9, 2023 | TEAS VOLUNTARY AMENDMENT RECEIVED |
| Monday, October 9, 2023 | PRELIMINARY/VOLUNTARY AMENDMENT - ENTERED |
| Wednesday, December 13, 2023 | ASSIGNED TO EXAMINER |
| Monday, December 18, 2023 | EXAMINERS AMENDMENT -WRITTEN |
| Monday, December 18, 2023 | EXAMINERS AMENDMENT E-MAILED |
| Monday, December 18, 2023 | NOTIFICATION OF EXAMINERS AMENDMENT E-MAILED |
| Tuesday, December 19, 2023 | ASSIGNED TO LIE |
| Tuesday, December 19, 2023 | EXAMINER'S AMENDMENT ENTERED |
| Friday, December 22, 2023 | APPROVED FOR PUB - PRINCIPAL REGISTER |
| Wednesday, January 10, 2024 | NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED |
| Tuesday, January 30, 2024 | PUBLISHED FOR OPPOSITION |
| Tuesday, January 30, 2024 | OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED |
| Wednesday, February 28, 2024 | TEAS CHANGE OF OWNER ADDRESS RECEIVED |
| Wednesday, February 28, 2024 | APPLICANT/CORRESPONDENCE CHANGES (NON-RESPONSIVE) ENTERED |
| Wednesday, February 28, 2024 | TEAS CHANGE OF CORRESPONDENCE RECEIVED |
| Tuesday, March 26, 2024 | NOA E-MAILED - SOU REQUIRED FROM APPLICANT |
| Thursday, September 12, 2024 | USE AMENDMENT FILED |
| Thursday, September 12, 2024 | TEAS STATEMENT OF USE RECEIVED |
| Thursday, September 12, 2024 | SOU TEAS EXTENSION RECEIVED |
| Thursday, September 12, 2024 | NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED |
| Thursday, September 12, 2024 | SOU EXTENSION 1 FILED |
| Thursday, November 14, 2024 | STATEMENT OF USE PROCESSING COMPLETE |
| Monday, December 9, 2024 | ALLOWED PRINCIPAL REGISTER - SOU ACCEPTED |
| Monday, December 9, 2024 | NOTICE OF ACCEPTANCE OF STATEMENT OF USE E-MAILED |
| Thursday, September 12, 2024 | SOU EXTENSION 1 GRANTED |
| Wednesday, November 13, 2024 | CASE ASSIGNED TO INTENT TO USE PARALEGAL |
